Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Post-FDA Evidence Needed To Inform Coverage Decisions – McClellan

This article was originally published in The Gray Sheet

Executive Summary

Generating comparative effectiveness data is most realistic after FDA approval, but improved mechanisms are needed, according to CMS Administrator Mark McClellan
Advertisement

Related Content

CMS Coverage Of Post-Approval Studies Seeks To Improve Data For NCDs
CMS Coverage Of Post-Approval Studies Seeks To Improve Data For NCDs
Congress Must Develop Cost Criteria For Coverage Decisions – NEJM Article
McClellan Discusses Research Alternatives To Comparative Clinical Trials
McClellan Discusses Research Alternatives To Comparative Clinical Trials
Congress Must Develop Cost Criteria For Coverage Decisions – NEJM Article
“Non-Burdensome” Cost-Effectiveness Trials Require Docs’ Help – McClellan
“Non-Burdensome” Cost-Effectiveness Trials Require Docs’ Help – McClellan
Advertisement
UsernamePublicRestriction

Register

MT020244

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel